1	Predictors of Mortality in Hospitalized Patients with COVID-19: A One-Year
2	Case-Control Study
3	Running title: COVID-19 and Prediction of Mortality
4	Laura Camacho-Domínguez ^{1,2} , Manuel Rojas ¹ , María Herrán ¹ , Yhojan
5	Rodríguez ^{1,2} , Santiago Beltrán ¹ , Paola Saboya Galindo ¹ , Nicolas Aguirre-Correal ¹ ,
6	María Espitia ¹ , Santiago García ¹ , Valeria Bejarano ¹ , Victoria Morales-González ¹ ,
7	Jaime Enrique Covaleda-Vargas ¹ , Mónica Rodríguez-Jiménez ¹ , Elizabeth
8	Zapata ^{1,2} , Diana M. Monsalve ¹ , Yeny Acosta-Ampudia ¹ , Juan-Manuel Anaya ³ ,
9	Carolina Ramírez-Santana ^{1*}
10	
11	¹ Center for Autoimmune Diseases Research (CREA), School of Medicine and
12	Health Sciences, Universidad del Rosario, Bogota, Colombia.
13	² Clínica del Occidente, Bogota, Colombia.
14	³ Health Research and Innovation Center at Coosalud, Cartagena 130001,
15	Colombia.
16	
17	Corresponding author
18	Carolina Ramírez-Santana, Ph.D.*
19	Center for Autoimmune Diseases Research (CREA), School of Medicine and
20	Health Sciences, Universidad del Rosario.
21	Carrera 24 # 63-C- 69, 110010, Bogota, Colombia.
22	E-mail address: heilv.ramirez@urosario.edu.co

23 Abstract (281 words)

Objective: To determine the associated factors with mortality, in addition to age
 and sex, in a high-complexity hospital in Bogota, Colombia, during the first year of
 the pandemic.

27 **Design:** A case-control study.

Setting: High-complexity center above 2,640 meters above sea level (masl) in
Colombia.

Methods: A case-control study was conducted on 564 patients admitted to the 30 hospital with confirmed COVID-19. Deceased patients (n: 282) and a control group 31 32 (n: 282), matched by age, sex, and month of admission, were included. Clinical and paraclinical variables were retrospectively obtained by systematic revision of 33 clinical records. Multiple imputations by chained equation (MICE) were 34 implemented to account for missing variables. Classification and regression trees 35 (CART) were estimated to evaluate the interaction of associated factors on 36 admission and their role in predicting mortality during hospitalization. 37

38 **Results:** Most of the patients included were males in the seventh decade of life. Most of the admissions occurred between July and August 2021. Surprisingly, 39 40 recovered patients reported heterogeneous symptomatology, whereas deceased patients were most likely to present respiratory distress, dyspnea, and seizures on 41 admission. In addition, the latter group exhibited a higher burden of comorbidities 42 43 and alterations in laboratory parameters. After the imputation of datasets, CART analysis estimated 14 clinical profiles based on respiratory distress, LDH, dyspnea, 44 hemoglobin, D-dimer, ferritin, blood urea nitrogen, C-reactive protein, PaO₂/FiO₂, 45

46	dysgeusia, total bilirubin, platelets, and gastroesophageal reflux disease. The
47	accuracy model for prediction was 85.6% (P < 0.0001).
48	Conclusion: Multivariate analysis yielded a reliable model to predict mortality in
49	COVID-19. This analysis revealed new interactions between clinical and
50	paraclinical features in addition to age and sex. Furthermore, this predictive model
51	could offer new clues for the personalized management of this condition in clinical
52	settings.
53	Keywords: SARS-CoV-2, COVID-19, Mortality, Predictors, Risk Factors.
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	

70

71 List of Abbreviations

- 72 ARBs: Angiotensin II receptor blockers.
- 73 ARDS: Acute respiratory distress syndrome.
- 74 BUN: Blood urea nitrogen.
- 75 CART: Classification and regression trees.
- 76 COVID-19: Coronavirus disease 2019.
- 77 CRP: C-reactive protein.
- 78 FiO_{2:} Fraction of inspired oxygen.
- 79 GERD: Gastroesophageal reflux disease
- 80 HIV: Human immunodeficiency.
- 81 ICU: Intensive care unit.
- 82 IL-1: Interleukin 1.
- 83 IL-6: Interleukin 6.
- 84 IQR: Interquartile range.
- 85 LDH: Lactate dehydrogenase.
- LOS: Length of stay.
- 87 Masl: Meters above sea level.
- 88 MICE: Multiple imputations by chained equation.
- 89 MV: Mechanical ventilation.
- 90 NSAIDs: Non-steroidal anti-inflammatory drugs.
- PaO₂/FiO₂: partial pressure of oxygen (PaO₂) to inspired (FiO₂) partial pressure of
- 92 oxygen ratio.
- 93 RT-PCR: Reverse transcriptase-polymerase chain reaction.

- 94 S/F: Ratio of oxygen saturation to fraction-inspired of oxygen.
- 95 SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.
- 96 TBC: Tuberculosis.
- 97 TBIL: Total bilirubin levels.
- 98 TNFα: Tumor necrosis factor-α.
- 99 WHO: World health organization.

- . . .

118

119 Introduction (Words 2857)

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory 120 syndrome coronavirus 2 (SARS-CoV-2), was first reported as an outbreak of new 121 122 viral pneumonia in Wuhan, China which was guickly distributed worldwide, generating a remarkable impact. Approximately 520,000,000 cases have been 123 reported, from which about 6,300,000 have died (1). This infection has a wide 124 125 range of clinical manifestations, ranging from asymptomatic disease to individuals who develop acute respiratory failure (2). However, most patients have mild 126 symptoms of cough, headache, myalgia, fever, and diarrhea; a smaller proportion 127 presents severe disease symptoms (1,2). The most common manifestation of 128 severity is dyspnea, which can be seen in up to 40% of patients and is usually 129 130 accompanied by hypoxemia (2).

The United States harbors almost a fifth of the infections worldwide and more than 131 1,000,000 deaths (1). It is followed by Brazil and India, with 665,000 and 524,000 132 133 deaths, respectively (1). Colombia occupies the twelfth position with approximately 140,000 deaths (1,3). Fatality, defined as the ratio between the cases of mortality 134 and the cases confirmed with SARS-CoV-2, has progressively decreased from 135 3.7% in March 2020 to 1.22% in the present day (4). Colombia presents a fatality 136 rate of 2.5%, higher than reported worldwide (3). Thus, further characterization of 137 138 mortality in Colombia is required to develop personalized risk profiles to better respond to the pandemic, especially in the current transition to endemic disease. 139 Patients with severe diseases are more likely to suffer complications associated 140 141 with higher mortality. One of the causes of this clinical deterioration is the cytokine

storm that generates a systemic inflammatory syndrome in which high cytokine 142 143 levels are associated with hyperactivation of the cellular response (5–8). Molecular mimicry between host and viral proteins has also been described, as well as direct 144 damage of the microorganism to tissues that present high expression of the 145 146 angiotensin-converting enzyme-2 receptor, as other possible causes (5–8). These processes will result, in most cases, in a respiratory distress syndrome 147 characterized by impaired gas exchange (6,8). They could also generate a 148 hypercoagulability state responsible for the increase in thrombotic events in 149 patients with this condition (5,7,9). 150

Multiple studies have found several factors associated with developing severe 151 152 disease. Age, sex, ethnicity, socioeconomic status, inflammatory markers, and 153 comorbid conditions have been widely associated with mortality. However, other 154 factors include ancestry, environmental exposures, viral mutations, and geographic diversity (10–12). A recent study in Bogota, a city above 2,640 meters above sea 155 level (masl) in Colombia, found that older age, low S/F: Ratio of oxygen saturation 156 157 to fraction-inspired of oxygen (S/F), and high lactate dehydrogenase (LDH) on 158 admission were predictors of mortality (13). However, observational studies have 159 shown that other variables, in addition to age and sex, could exhibit interactions among them, which have been poorly characterized in our population (14). 160

Herein, we conducted a one-year case-control study to characterize the clinical and paraclinical factors associated with mortality during the first year of the pandemic. We implemented supervised machine learning algorithms to evaluate the interactions among variables and their potential to predict mortality on

admission. We adjusted the analysis by monthly progression, which may account

166 for changes in the mortality rates due to viral mutations during the pandemic.

167

168 Methods

169 Study design

This case-control study was conducted in Clínica de Occidente, a tertiary referral 170 center in Bogota, Colombia. The study screening was from February 29th, 2020, to 171 172 March 1st, 2021. Included patients were selected from 4,163 cases positive for SARS-CoV-2 by reverse transcriptase-polymerase chain reaction (RT-PCR) and 173 who attended the emergency room during the first year of the pandemic with 174 175 complete clinical records. A non-probabilistic convenience sampling included a total of 282 deceased patients. An additional group of 282 patients, who were 176 177 hospitalized but recovered from COVID-19, was included as the control group. These controls were matched to deceased patients by age, sex, and month of 178 179 consultation (to account for viral mutations). None of the patients received 180 vaccinations during the study timeframe, and the included patients attended the emergency room between April 3rd, 2020, to January 30th, 2021. This was a low-181 risk study according to the resolution 8430 of 1993 from the Ministry of Health of 182 Colombia. The institutional review board of Clínica de Occidente approved the 183 study design. 184

185

186 Inclusion and exclusion criteria

Inclusion criteria comprised the following: (1) aged at least 18 years; (2) COVID-19
 diagnosis based on RT-PCR testing; (3) hospitalized patients; and (4) death

registered in death certificate adequately filled out by medical doctors who certified COVID-19 as the cause of death. In the case of controls, they were hospitalized but recovered during the hospitalization and received ambulatory management.

isi bu recevered during the neepitalization and received ambalatory managemen

192 Patients referred to another clinical setting were excluded from the analysis.

193 **Clinical variables and data extraction**

194 Medical records were reviewed through access to the server assigned by the hospital. Information considered relevant for this investigation was extracted, 195 including sociodemographic variables, clinical features (signs, 196 symptoms. laboratories on admission), past medical history, in-hospital management (i.e., 197 198 requirement of ventilatory support, intensive care unit (ICU) admission, vasopressor support), medications administered on admission, organ-specific and 199 200 systemic outcomes during hospitalization (Table 1, 2 and 3). Research participants 201 remained anonymous at all times. All data were collected in an electronic and secure database as described elsewhere (15). 202

203

204 Patient and Public Involvement

Patients or the public were not involved in the research's design, conduct,
 reporting, or dissemination plans.

207

208 Statistical analyses

209 Univariate descriptive statistics were performed. Categorical variables were 210 analyzed using frequencies, and continuous quantitative variables were expressed 211 as the median and interquartile range (IQR). The Mann–Whitney U-test or Fisher

exact tests were used based on the results. None of the included parameters weresubjected to statistical transformation or normalization.

The missing data rates for each variable in our study are shown in Tables 1,2,3 214 and Figure 1. Most of the missingness was secondary to the lack of 215 216 standardization at the beginning of the pandemic for laboratory values required in the follow-up and management of the patients. We used multiple imputations by 217 218 chained equation (MICE) to create and analyze five multiply imputed datasets for variables with less than 80% of data missingness (Table 3). Multiple imputations 219 are considered cutting-edge by methodologists since they enhance accuracy and 220 221 statistical power when compared to other missing data strategies. Incomplete 222 variables were imputed under wholly conditional specification using the default 223 settings of the MICE 3.14 package (16).

Then, we built classification and regression trees (CART) to evaluate the 224 relationship between clinical variables and mortality in each imputed dataset on 225 226 admission. This strategy aims to identify, at each partitioning step, the best 227 predictive variable and corresponding splitting value while optimizing a statistical 228 criterion. Variables with a p-value ≤ 0.25 in the bivariate analysis were included in the model. Each model's confusion matrix was built to determine MICE's best 229 predictive model from the five imputed datasets and was reported accordingly. The 230 significance level of the study was set to 0.05. Statistical analyses were done using 231 232 R software version 4.1.2.

233

234 **Results**

235 General characteristics

The general characteristics of patients are shown in Table 1. The median age of the patients and sex were similar between groups. On admission, fever, odynophagia, anosmia, dysgeusia, chest pain, myalgias, arthralgias, headache, and diarrhea were most commonly reported in recovered patients. General discomfort, dyspnea, respiratory distress, and seizures were most common in deceased patients (Table 1). Most of the included patients visited the hospital between July and September 2020.

243

244 **Treatment, comorbidities, and outcomes**

Heart failure, hypertension, obesity, type II diabetes, and active smoking were most 245 246 common in deceased patients. On the other hand, gastroesophageal reflux 247 disease (GERD) was mainly reported in recovered patients (Table 1). Deceased patients were more likely to receive corticosteroids and antibiotics upon admission 248 (Table 2). Few patients received antimalarials or antivirals. On admission, 249 250 deceased patients exhibited paraclinical alterations in inflammatory markers 251 related to hematological, liver, and pulmonary function (Table 3). This was further confirmed during the follow-up, given the higher rates of systemic and organic 252 compromise presented during the hospitalization (Table 3). 253

254

255 Missing data imputation

The missing values across the variables ranged between 18.79% and 98.94%. The high missingness rate was related to laboratory variables, mainly albumin, creatine kinase, procalcitonin, and the erythrocyte sedimentation rate (Table 3 and Figure 1 A-C), whereas clinical characteristics, in-hospital admission management, and

comorbidities did not have missed values. Since the objective of our study was to evaluate the interaction between clinical and paraclinical factors on admission in predicting mortality, we conducted a MICE imputation strategy to include all the cases in multivariate models.

We created and analyzed five multiply imputed datasets for variables with less than 80% of data missingness (Figure 1C). The sensitivity analysis yielded no significant differences between the primary and the five imputed datasets (Table 4). This confirmed that the distribution of imputed data was similar to the original dataset, as well as the stability of the imputation models.

269

270 A multivariate predictive model for mortality

After imputation, we aimed to evaluate the interaction of multiple variables in predicting mortality on admission. We estimated CART models using the variables with p-values ≤ 0.25 from the bivariate analysis for each imputed dataset. We constructed a confusion matrix for each CART model to estimate the best-fitted model to the data. After this analysis, we selected the best model based on estimated accuracy (Figure 2).

The analysis revealed that multiple variables interacted in the prediction of mortality. Respiratory distress on admission was the first splitting variable from the tree. Then, the second node was determined by LDH and dyspnea. The former interacted with hemoglobin, D-dimer, ferritin, blood urea nitrogen (BUN), C-reactive protein (CRP), partial pressure of oxygen (PaO₂) to inspired (FiO₂) partial pressure of oxygen ratio (PaO₂/FiO₂), dysgeusia, total bilirubin levels (TBIL), and platelets. The latter interacted with GERD (Figure 2).

284

285 **Discussion**

A few published papers have previously characterized the risk factors associated 286 with COVID-19 mortality in Latin American patients (17,18) Therefore, the present 287 study highlights multiple variables, including laboratory abnormalities and clinical 288 features associated with COVID-19 mortality. The main findings in our study were 289 significant associations between TBIL, ferritin, D-Dimer levels, dyspnea, GERD, 290 and increased risk of mortality in COVID-19 patients. In contrast, dysgeusia was 291 associated with a better prognosis. Other trends were found between BUN, 292 293 respiratory distress, platelet count, PaO2/FiO2, and CRP.

294 Increased TBIL was associated with poor COVID-19 outcomes. This is consistent with previous findings (19) which suggest that high TBIL may reflect a severe level 295 296 of hepatic injury among severely ill COVID-19 patients, possibly due to direct effect. immune-mediated effects. 297 cytopathic hypoxia-induced changes. microvascular thrombosis, among others (20,21). It is not surprising that some 298 299 authors have also considered that TIBL at admission is directly correlated with the hospital progression of COVID-19 (20). 300

Serum ferritin has been cited as one of the mortality indicators in COVID-19 patients due to its ability to assess intracellular iron status (22,23). These events are common in the pathogenesis of uncontrolled inflammation and massive cytokine release, supporting the hypothesis that hyper-inflammation is a possible pathogenic mechanism in COVID-19 and, therefore, the rise of serum ferritin level findings (23). Multiple studies have also suggested that higher levels of CRP on admission are linked to disease progression, severity, and death (24–26).

However, we found that CRP interacts with other variables related to inflammation
 and organ damage implicated in mortality.

The D-dimer antigen is a unique marker of fibrin degradation that may indicate 310 infection-related coagulation effects (27,28). Furthermore, previous studies have 311 312 found that critically ill patients with COVID-19 have extremely high D-dimer levels. which can lead to clotting disorders and peripheral microthrombi formation (29). In 313 this study, we found that higher levels of D-dimer at admission were associated 314 315 with increased mortality risk in COVID-19 patients. This is consistent with other studies that have found D-dimer as another crucial prognostic factor in estimating 316 317 mortality in COVID-19 patients (30).

Similar results from other studies also elicited dyspnea as a significant clinical 318 variable for mortality prediction among COVID-19 patients (31). A meta-analysis 319 320 study by He et al. showed that dyspnea was the main difference between mild and severe COVID-19 [40], and another study confirmed this observation (32). On the 321 other hand, in patients with gastrointestinal symptoms during COVID-19, GERD 322 323 appeared to be a protective factor for acute respiratory distress syndrome (ARDS), and mortality possible due to a conversely increased acidic environment 324 associated with GERD that suppresses COVID-19 viral load at the gastrointestinal 325 326 point of entry, favoring a milder disease course (33). In our study, similar results were obtained: COVID-19 patients without GERD had an increased mortality risk. 327

Interestingly, dysgeusia was associated with lower odds of death in our study. This might be related to a different inflammatory profile with a better local immune response, which could limit the spread of the virus in the body, resulting in less severe disease and a strong local inflammatory response that could mainly affect

taste receptors. However, there is still a lack of information regarding dysgeusia,
perhaps because of the heterogeneity in how it has been assessed and defined
(34). On the other hand, previous studies have focused on anosmia as a protective
factor for mortality (35,36).

A significant association was found between BUN and mortality risk among COVID-19 patients. Other studies also supported our results since BUN has been previously considered a death-related feature (37). Although COVID-19 impacts mainly the lung, it can also affect the kidney, and the increase in BUN may reflect kidney injury along with other biomarkers. Moreover, kidney involvement in severe COVID-19 patients has been frequently observed (37,38).

342 The glycolytic enzyme LDH has long been identified as an inflammation biomarker that plays a crucial role in the anaerobic glycolysis pathway and increases in the 343 bloodstream under conditions of membrane instability (39). In most studies, 344 authors have concluded that LDH is a deleterious prognostic biomarker with high 345 346 accuracy for predicting in-hospital mortality in severe and critically ill patients with 347 COVID-19 (40,41). In addition, thrombocytopenia has also been reported in COVID-19 patients and is considered a potential risk factor for mortality in this 348 group of patients (42,43). The PaO2/FiO2 partial pressure of oxygen has also been 349 widely used to diagnose and assess the severity of patients with ARDS (44,45). 350

Since several factors have been related to the incidence of mortality in COVID-19, the interaction among them may provide better insights into predicting deleterious outcomes. A similar study in Bogota found that older age, low S/F, and high LDH on admission were predictors of mortality (13). This study assessed the interaction of variables by CART analysis, yielding five plausible groups. However, it is unclear 356 whether the multivariate model included all the patients since information on 357 missing data is unavailable, and the model accuracy is unknown.

In contrast, Afrash et al.(46) developed hybrid machine-learning algorithms to predict mortality. Authors found that the mixture of variables such as length of stay (LOS), age, cough, respiratory intubation, dyspnea, cardiovascular disease, leukocytosis, BUN, CRP, and pleural effusion yielded a high accuracy (90%), specificity (83%), and sensitivity (97%). However, it includes variables that depend on the patient follow-up (i.e., LOS), thus hindering its applicability during admission to the emergency room, that is, during the early stages of the disease.

Several manuscripts have developed similar approaches involving different 365 366 variables in the prediction of mortality; some of them include dyspnea (46,47), BUN, platelet count (47,48), sex (47), age (46,48-51), cough (46), weight (49), 367 368 cardiovascular disease (46), orotracheal intubation (46), and pleural effusion (46,49), respiratory rate (47), fraction of inspired oxygen (47), blood oxygen 369 370 saturation (47,48) pH (47), aspartate aminotransferase levels (47), estimated 371 glomerular filtration rate (47), lymphocyte count (49,52), white blood cell count (46,48), creatine (51) lactic acid (52) and serum calcium (52). However, most of 372 them do not focus on the interaction of such variables on hospital admission, and 373 their interpretability by clinicians is difficult. In this line, our study provides a novel, 374 biologically plausible, and reliable model with clinical applicability in the emergency 375 376 room during patient admission. Further studies are necessary to evaluate whether our model may help to predict the efficacy of the rapeutic strategies or outpatient 377 mortality (during post-COVID syndrome). 378

Study limitations must be acknowledged. It was a single-center retrospective study 379 380 based on clinical records. This could have prone our study to reporting bias, for example, on time from symptoms onset to consultation or clinical features. In 381 addition, the therapeutic strategies changed during the pandemic; however, our 382 study was matched by month of consultation, making this variable an unlikely 383 confounding/interaction factor for our results. The objective of our study was to 384 uncover other risk factors for mortality besides sex and age. In this line, the 385 adjustment for age, sex, and month of consultation allowed the discovery of new 386 interactions for mortality prediction. The lack of follow-up beyond the hospitalization 387 388 in recovered patients could have offered new insights into mortality beyond the clinical settings. Another potential shortcoming of the present study is that latent 389 390 autoimmunity, especially the positivity for anti-IFN- α antibodies, was not evaluated. Further analysis involving such variables could improve our model's reliability and 391 predictive accuracy. 392

393

394 **Conclusions**

Our study demonstrates the highly complex interactions among different risk factors to predict mortality in COVID-19, in addition to age and sex. This predictive approach may also provide new insights into the tailored management of this illness in several clinical settings, specifically in Colombian clinical settings. This study should encourage the follow-up of recovered patients beyond hospitalization and despite their clinical status during acute COVID-19.

401

402 Role of the Funder/Sponsor

403	The funders had no role in the design and conduct of the study; collection,
404	management, analysis, and interpretation of the data; preparation, review, or
405	approval of the manuscript; and decision to submit the manuscript for publication.
406	Funding
407	This study was supported by a grant from Universidad del Rosario (ABN011)
408	Bogota, Colombia.
409	Ethics approval and consent to participate
410	The institutional review board of Clínica de Occidente approved the study design.
411	Written informed consent was not obtained from participants since the study was
412	based on a retrospective review of clinical records. It was a low-risk study
413	according to the resolution 8430 of 1993 from the Ministry of Health of Colombia.
414	The study was conducted following the principles stated in the Declaration of
415	Helsinki and Good Clinical Practice guidelines.
416	Consent to publish
417	None of the patients were required to consent to publish, given the study's
418	retrospective nature.
419	Declaration of competing interest
420	None.
421	Author Contributions Statement
422	Conceptualization: JMA; Acquisition of data: LCD, MR, YR, MH, SB, PSG, NAC,
423	ME, SG, VB, VM, JEC, EZ; Methodology: JMA, LCD, MR; Statistical Analysis: MR;

- Funding acquisition: JMA, CRS; Center Coordination: YR, MR; Writing & editing: 424
- LCD, MR, CRS, YAA, DMM. All authors read and approved the final version of this 425
- 426 manuscript.

427 Acknowledgments

- The authors would like to thank the medical staff of Clinical del Occidente, Dr. Ivan
- 429 Torres, and Maria Claudia Fuentes, for their assistance at the beginning of the
- 430 study.

431 Availability of data and materials

432 Data will be available upon request to the corresponding author.

433 **About the Author**

- 434 Dr. Camacho-Domínguez is a research assiant in autoimmune diseases at Center
- 435 for Autoimmune Diseases Research (CREA), School of Medicine and Health
- 436 Sciences, Universidad del Rosario, Bogota, Colombia. Her primary research
- 437 interests include infectious diseases, immunology, and rheumatology.

438

439 **References**

- 1. World Health Organization. WHO COVID-19 Dashboard. Geneva; 2020.
- 441 2. Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. N Engl J Med
 442 [Internet]. 2020 Oct 29 [cited 2022 Sep 23];383(18):1757–66. Available from:
 443 https://pubmed.ncbi.nlm.nih.gov/32329974/
- 444 3. Instituto Nacional de Salud. COVID-19 en Colombia . 2020.
- 445 4. Ritchie H, Mathieu E. Coronavirus Pandemic (COVID-19). 2020.
- 5. Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, et al. COVID-19:
 A Multidisciplinary Review. Front Public Health [Internet]. 2020 Jul 29 [cited
 2022 Sep 23];8. Available from: https://pubmed.ncbi.nlm.nih.gov/32850602/
- 6. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med
 [Internet]. 2020 Dec 17 [cited 2022 Sep 23];383(25):2451–60. Available from: https://pubmed.ncbi.nlm.nih.gov/32412710/
- 452 7. Parasher A. COVID-19: Current understanding of its Pathophysiology,
- 453 Clinical presentation and Treatment. Postgrad Med J [Internet]. 2021 May 1 454 [cited 2022 Sep 23];97(1147):312–20. Available from:
- 455 https://pubmed.ncbi.nlm.nih.gov/32978337/

Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med [Internet]. 2020

456

8.

Dec 3 [cited 2022 Sep 23];383(23):2255-73. Available from: 457 https://pubmed.ncbi.nlm.nih.gov/33264547/ 458 Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and 459 9. Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med 460 [Internet]. 2020 Apr 23 [cited 2022 Sep 23];382(17):e38. Available from: 461 https://pubmed.ncbi.nlm.nih.gov/32268022/ 462 463 10. Hu J, Li C, Wang S, Li T, Zhang H. Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data. Hum Genomics 464 [Internet]. 2021 Dec 1 [cited 2022 Sep 23];15(1). Available from: 465 https://pubmed.ncbi.nlm.nih.gov/33536081/ 466 11. Pansini R, Fornacca D. COVID-19 Higher Mortality in Chinese Regions With 467 Chronic Exposure to Lower Air Quality. Front Public Health [Internet]. 2021 468 Jan 22 [cited 2022 Sep 23];8. Available from: 469 https://pubmed.ncbi.nlm.nih.gov/33585383/ 470 Anaele BI, Doran C, McIntire R. Visualizing COVID-19 Mortality Rates and 471 12. African-American Populations in the USA and Pennsylvania. J Racial Ethn 472 Health Disparities [Internet]. 2021 Dec 1 [cited 2022 Sep 23];8(6):1356-63. 473 Available from: https://pubmed.ncbi.nlm.nih.gov/33565050/ 474 Rodriguez Lima DR, Pinzón Rondón ÁM, Rubio Ramos C, Pinilla Rojas DI, 475 13. Niño Orrego MJ, Díaz Quiroz MA, et al. Clinical characteristics and mortality 476 associated with COVID-19 at high altitude: a cohort of 5161 patients in 477 Bogotá, Colombia. Int J Emerg Med [Internet]. 2022 Dec 1 [cited 2022 Sep 478 23];15(1). Available from: https://pubmed.ncbi.nlm.nih.gov/35597911/ 479 Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk 480 14. factors for mortality in patients with Coronavirus disease 2019 (COVID-19) 481 infection: a systematic review and meta-analysis of observational studies. 482 Aging Male [Internet]. 2020 [cited 2022 Sep 23];23(5):1416-24. Available 483 from: https://pubmed.ncbi.nlm.nih.gov/32508193/ 484 Rojas M, Rodriguez Y, Pacheco Y, Zapata E, Monsalve DM, Mantilla RD, et 485 15. al. Resilience in women with autoimmune rheumatic diseases. Joint Bone 486 Spine [Internet]. 2018 Dec 1 [cited 2022 Sep 23]:85(6):715-20. Available 487 from: https://pubmed.ncbi.nlm.nih.gov/29289647/ 488 van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by 489 16. 490 chained equations in R. J Stat Softw. 2011 Dec;45(3):1-67. Araujo M, Ossandón P, Abarca AM, Menjiba AM, Muñoz AM. Pronóstico de 491 17. pacientes hospitalizados por COVID-19 en un centro terciario en Chile: 492 estudio de cohorte. Medwave. 2020 Nov 17;20(10):e8066. 493

18. Alonso R, Camon AM, Cardozo C, Albiach L, Agüero D, Marcos MA, et al. 494 Clinical Presentation and Outcome of COVID-19 in a Latin American Versus 495 Spanish Population: Matched Case-Control Study. Infect Dis Ther [Internet]. 496 2022 Jun 1 [cited 2022 Sep 23];11(3):1243–51. Available from: 497 https://pubmed.ncbi.nlm.nih.gov/35476212/ 498 Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, et al. Longitudinal 19. 499 Association Between Markers of Liver Injury and Mortality in COVID-19 in 500 China. Hepatology [Internet]. 2020 Aug 1 [cited 2022 Sep 23];72(2):389-98. 501 Available from: https://pubmed.ncbi.nlm.nih.gov/32359177/ 502 Russo A, Pisaturo M, Palladino R, Maggi P, Numis FG, Gentile I, et al. 503 20. Prognostic Value of Transaminases and Bilirubin Levels at Admission to 504 505 Hospital on Disease Progression and Mortality in Patients with COVID-19-An Observational Retrospective Study. Pathogens [Internet]. 2022 Jun 1 [cited 506 2022 Sep 23];11(6). Available from: 507 https://pubmed.ncbi.nlm.nih.gov/35745506/ 508 Dawood DRM, Salum GM, El-Meguid MA. The Impact of COVID-19 on Liver 509 21. Injury. Am J Med Sci [Internet]. 2022 Feb 1 [cited 2022 Sep 23];363(2):94-510 103. Available from: https://pubmed.ncbi.nlm.nih.gov/34752738/ 511 Zhou S, Li H, Li S. The Associations of Iron Related Biomarkers with Risk, 512 22. Clinical Severity and Mortality in SARS-CoV-2 Patients: A Meta-Analysis. 513 Nutrients [Internet]. 2022 Aug 1 [cited 2022 Sep 23];14(16). Available from: 514 https://pubmed.ncbi.nlm.nih.gov/36014912/ 515 Dahan S, Segal G, Katz I, Hellou T, Tietel M, Bryk G, et al. Ferritin as a 23. 516 Marker of Severity in COVID-19 Patients: A Fatal Correlation. Isr Med Assoc 517 J [Internet]. 2020 Aug 1 [cited 2022 Sep 23];22(8):494–500. Available from: 518 https://pubmed.ncbi.nlm.nih.gov/33236582/ 519 Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is 24. 520 positively associated with the severity of COVID-19. Ann Clin Microbiol 521 Antimicrob [Internet]. 2020 [cited 2022 Sep 24];19(1). Available from: 522 https://pubmed.ncbi.nlm.nih.gov/32414383/ 523 Lavillegrand JR, Garnier M, Spaeth A, Mario N, Hariri G, Pilon A, et al. 524 25. Elevated plasma IL-6 and CRP levels are associated with adverse clinical 525 outcomes and death in critically ill SARS-CoV-2 patients: inflammatory 526 response of SARS-CoV-2 patients. Ann Intensive Care [Internet]. 2021 Dec 1 527 [cited 2022 Sep 24];11(1). Available from: 528 https://pubmed.ncbi.nlm.nih.gov/33439360/ 529 Pál K, Molnar AA, Hu anu A, Szederjesi J, Branea I, Timár Á, et al. 530 26. Inflammatory Biomarkers Associated with In-Hospital Mortality in Critical 531 COVID-19 Patients. Int J Mol Sci [Internet]. 2022 Sep 9 [cited 2022 Sep 532

533 534		24];23(18):10423. Available from: https://pubmed.ncbi.nlm.nih.gov/36142336/
535 536 537 538	27.	Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood [Internet]. 2009 Mar 26 [cited 2022 Sep 24];113(13):2878–87. Available from: https://pubmed.ncbi.nlm.nih.gov/19008457/
539 540 541 542	28.	Ye W, Chen G, Li X, Lan X, Ji C, Hou M, et al. Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID- 19. Respir Res [Internet]. 2020 Jul 3 [cited 2022 Sep 24];21(1). Available from: https://pubmed.ncbi.nlm.nih.gov/32620118/
543 544 545 546	29.	Hilda F, Liana P, Nurtjahyo A, Hudari H, Sari NP, Umar TP, et al. D-Dimer as a Sensitive Biomarker of Survival Rate in Patients with COVID-19. Eurasian J Med [Internet]. 2022 Aug 11 [cited 2022 Sep 24]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/35950823
547 548 549	30.	Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021 Dec 21;21(1):855.
550 551 552 553 554	31.	Lee JH, Ahn JS, Chung MJ, Jeong YJ, Kim JH, Lim JK, et al. Development and Validation of a Multimodal-Based Prognosis and Intervention Prediction Model for COVID-19 Patients in a Multicenter Cohort. Sensors (Basel) [Internet]. 2022 Jul 1 [cited 2022 Sep 24];22(13). Available from: https://pubmed.ncbi.nlm.nih.gov/35808502/
555 556 557 558	32.	Yang L, Jin J, Luo W, Gan Y, Chen B, Li W. Risk factors for predicting mortality of COVID-19 patients: A systematic review and meta-analysis. PLoS One [Internet]. 2020 Nov 1 [cited 2022 Sep 24];15(11). Available from: https://pubmed.ncbi.nlm.nih.gov/33253244/
559 560 561 562	33.	Patil N, Kalgotra P, Sundaram S, Melquist S, Parasa S, Desai M, et al. Factors associated with poor outcomes among COVID-19 patients with gastrointestinal symptoms. Gastro hep advances [Internet]. 2022 Aug [cited 2022 Sep 24]; Available from: https://pubmed.ncbi.nlm.nih.gov/36043056/
563 564 565	34.	Carrillo-Larco RM, Altez-Fernandez C. Anosmia and dysgeusia in COVID-19: A systematic review. Wellcome Open Res [Internet]. 2020 [cited 2022 Sep 24];5. Available from: https://pubmed.ncbi.nlm.nih.gov/32587902/
566 567 568 569	35.	Talavera B, García-Azorín D, Martínez-Pías E, Trigo J, Hernández-Pérez I, Valle-Peñacoba G, et al. Anosmia is associated with lower in-hospital mortality in COVID-19. J Neurol Sci [Internet]. 2020 Dec 15 [cited 2022 Sep 24];419. Available from: https://pubmed.ncbi.nlm.nih.gov/33035870/

570 571 572 573 574	36.	Lechien JR, Chiesa-Estomba CM, Beckers E, Mustin V, Ducarme M, Journe F, et al. Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. J Intern Med [Internet]. 2021 Aug 1 [cited 2022 Sep 24];290(2):451–61. Available from: https://pubmed.ncbi.nlm.nih.gov/33403772/
575 576 577 578	37.	Zadeh Hosseingholi E, Maddahi S, Jabbari S, Molavi G. Identification of High Death Risk Coronavirus Disease-19 Patients using Blood Tests. Adv Biomed Res [Internet]. 2022 [cited 2022 Sep 24];11(1):58. Available from: https://pubmed.ncbi.nlm.nih.gov/36124024/
579 580 581 582	38.	Liu YM, Xie J, Chen MM, Zhang X, Cheng X, Li H, et al. Kidney Function Indicators Predict Adverse Outcomes of COVID-19. Med (N Y) [Internet]. 2021 Jan 15 [cited 2022 Sep 24];2(1):38-48.e2. Available from: https://pubmed.ncbi.nlm.nih.gov/33043313/
583 584 585 586	39.	Gupta GS. The Lactate and the Lactate Dehydrogenase in Inflammatory Diseases and Major Risk Factors in COVID-19 Patients. Inflammation [Internet]. 2022 [cited 2022 Sep 24];1. Available from: /pmc/articles/PMC9117991/
587 588 589 590	40.	Dong X, Sun L, Li Y. Prognostic value of lactate dehydrogenase for in- hospital mortality in severe and critically ill patients with COVID-19. Int J Med Sci [Internet]. 2020 [cited 2022 Sep 24];17(14):2225–31. Available from: https://pubmed.ncbi.nlm.nih.gov/32922185/
591 592 593 594 595	41.	Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med [Internet]. 2020 Jul 1 [cited 2022 Sep 24];180(7):934–43. Available from: https://pubmed.ncbi.nlm.nih.gov/32167524/
596 597 598 599	42.	Amgalan A, Othman M. Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. Platelets [Internet]. 2020 Aug 17 [cited 2022 Sep 24];31(6):740–5. Available from: https://pubmed.ncbi.nlm.nih.gov/32456506/
600 601 602 603	43.	Yuan Y, Wang G, Chen X, Ye XL, Li XK, Li R, et al. Thrombocytopenia and increased risk of adverse outcome in COVID-19 patients. PeerJ [Internet]. 2022 Jun 30 [cited 2022 Sep 24];10. Available from: https://pubmed.ncbi.nlm.nih.gov/35791362/
604 605 606 607	44.	Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA [Internet]. 2012 Jun 13 [cited 2022 Sep 24];307(23):2526–33. Available from: https://pubmed.ncbi.nlm.nih.gov/22797452/

608 609 610 611 612	45.	Villar J, Blanco J, del Campo R, Andaluz-Ojeda D, Díaz-Domínguez FJ, Muriel A, et al. Assessment of PaO ₂ /FiO ₂ for stratification of patients with moderate and severe acute respiratory distress syndrome. BMJ Open [Internet]. 2015 Mar 27 [cited 2022 Sep 24];5(3). Available from: https://pubmed.ncbi.nlm.nih.gov/25818272/
613 614 615 616	46.	Afrash MR, Shanbehzadeh M, Kazemi-Arpanahi H. Predicting Risk of Mortality in COVID-19 Hospitalized Patients using Hybrid Machine Learning Algorithms. J Biomed Phys Eng [Internet]. 2022 Dec 1 [cited 2023 Jan 1];12(6):611–26. Available from: https://pubmed.ncbi.nlm.nih.gov/36569564/
617 618 619 620 621	47.	Weizman O, Duceau B, Trimaille A, Pommier T, Cellier J, Geneste L, et al. Machine learning-based scoring system to predict in-hospital outcomes in patients hospitalized with COVID-19. Arch Cardiovasc Dis [Internet]. 2022 Dec [cited 2023 Jan 1];115(12). Available from: https://pubmed.ncbi.nlm.nih.gov/36376208/
622 623 624 625 626	48.	Xu Y, Trivedi A, Becker N, Blazes M, Ferres JL, Lee A, et al. Machine learning-based derivation and external validation of a tool to predict death and development of organ failure in hospitalized patients with COVID-19. Sci Rep [Internet]. 2022 Dec 1 [cited 2023 Jan 1];12(1). Available from: https://pubmed.ncbi.nlm.nih.gov/36209335/
627 628 629 630 631	49.	Padilha DMH, Garcia GR, Liveraro GSS, Mendes MCS, Takahashi MES, Lascala F, et al. Construction of a nomogram for predicting COVID-19 in- hospital mortality: A machine learning analysis. Inform Med Unlocked [Internet]. 2023 Jan 1 [cited 2023 Jan 1];36. Available from: https://pubmed.ncbi.nlm.nih.gov/36474601/
632 633 634 635	50.	Yu Z, Li X, Zhao J, Sun S. Identification of hospitalized mortality of patients with COVID-19 by machine learning models based on blood inflammatory cytokines. Front Public Health [Internet]. 2022 Nov 17 [cited 2023 Jan 1];10. Available from: https://pubmed.ncbi.nlm.nih.gov/36466533/
636 637 638 639 640	51.	González-Cebrián A, Borràs-Ferrís J, Ordovás-Baines JP, Hermenegildo- Caudevilla M, Climente-Marti M, Tarazona S, et al. Machine-learning-derived predictive score for early estimation of COVID-19 mortality risk in hospitalized patients. PLoS One [Internet]. 2022 Sep 1 [cited 2023 Jan 1];17(9). Available from: https://pubmed.ncbi.nlm.nih.gov/36137106/
641 642 643	52.	Ustebay S, Sarmis A, Kaya GK, Sujan M. A comparison of machine learning algorithms in predicting COVID-19 prognostics. Intern Emerg Med [Internet]. 2022 [cited 2023. Jan 1]: Available from:
644 645		https://pubmed.ncbi.nlm.nih.gov/36116079/

Recovered patients (n=282)	Deceased patients (n=282)	P-value ^a	Misssingness (n: 564)
	1	L	
		1.0000	0 (0%)
110 (39.0%)	110 (39.0%)		
172 (61%)	172 (61%)		
68 (60 - 77)	69 (60 - 78)	0.4843	0 (0%)
		1.0000	0 (0%)
4 (1.4%)	4 (1.4%)		
8 (2.8%)	8 (2.8%)		
17 (6.0%)	17 (6.0%)		
77 (27.3%)	77 (27.3%)		
49 (17.4%)	49 (17.4%)		
20 (7.1%)	20 (7.1%)		
16 (5.7%)	16 (5.7%)		
9 (3.2%)	9 (3.2%)		
37 (13.1%)	37 (13.1%)		
45 (16.0%)	45 (16.0%)		
167 (59.2%)	138 (48.9%)	0.0179	0 (0%)
41 (14.5%)	45 (16.0%)	0.7255	0 (0%)
1 (0.4%)	1 (0.4%)	1.0000	0 (0%)
177 (62.8%)	162 (57.4%)	0.2286	0 (0%)
66 (23.4%)	35 (12.4%)	0.0009	0 (0%)
	Recovered patients (n=282) 110 (39.0%) 172 (61%) 68 (60 - 77) 4 (1.4%) 8 (2.8%) 17 (6.0%) 77 (27.3%) 49 (17.4%) 20 (7.1%) 16 (5.7%) 9 (3.2%) 37 (13.1%) 45 (16.0%) 107 (59.2%) 41 (14.5%) 177 (62.8%) 66 (23.4%)	Recovered patients (n=282) Deceased patients (n=282) 110 (39.0%) 110 (39.0%) 172 (61%) 172 (61%) 68 (60 - 77) 69 (60 - 78) 4 (1.4%) 4 (1.4%) 8 (2.8%) 8 (2.8%) 17 (6.0%) 17 (6.0%) 77 (27.3%) 77 (27.3%) 49 (17.4%) 49 (17.4%) 20 (7.1%) 20 (7.1%) 16 (5.7%) 16 (5.7%) 9 (3.2%) 9 (3.2%) 37 (13.1%) 37 (13.1%) 45 (16.0%) 45 (16.0%) 110 (14.5%) 138 (48.9%) 41 (14.5%) 162 (57.4%) 177 (62.8%) 35 (12.4%)	Recovered patients (n=282) Deceased patients (n=282) P-value ^a 110 (39.0%) 110 (39.0%) 1.0000 172 (61%) 172 (61%) 0.4843 68 (60 - 77) 69 (60 - 78) 0.4843 4 (1.4%) 4 (1.4%) 1.0000 4 (1.4%) 8 (2.8%) 1.0000 177 (60%) 177 (60%) 177 (60%) 77 (27.3%) 77 (27.3%) 149 (17.4%) 20 (7.1%) 20 (7.1%) 16 (5.7%) 9 (3.2%) 9 (3.2%) 37 (13.1%) 45 (16.0%) 37 (13.1%) 138 (48.9%) 0.0179 41 (14.5%) 138 (48.9%) 0.2286 10.4%) 1 (0.4%) 1.0000

Anosmia	32 (11.3%)	7 (2.5%)	< 1e-04	0 (0%)
Dysgeusia	34 (12.1%)	7 (2.5%)	< 1e-04	0 (0%)
Rhinorrhea	27 (9.6%)	18 (6.4%)	0.2134	0 (0%)
Wheezing	4 (1.4%)	4 (1.4%)	1.0000	0 (0%)
Chest Pain	55 (19.5%)	35 (12.4%)	0.0285	0 (0%)
Myalgias	70 (24.8%)	40 (14.2%)	0.0020	0 (0%)
Arthralgias	31 (11.0%)	14 (5.0%)	0.0122	0 (0%)
General discomfort	165 (58.5%)	226 (80.1%)	< 1e-04	0 (0%)
Dyspnea	137 (48.6%)	227 (80.5%)	< 1e-04	0 (0%)
Inability to walk	1 (0.4%)	0 (0.0%)	1.0000	0 (0%)
Respiratory distress	22 (7.8%)	149 (52.8%)	< 1e-04	0 (0%)
Headache	66 (23.4%)	29 (10.3%)	< 1e-04	0 (0%)
Seizure	0 (0.0%)	5 (1.8%)	0.0614	0 (0%)
Abdominal pain	21 (7.4%)	21 (7.4%)	1.0000	0 (0%)
Nausea/Vomiting	27 (9.6%)	15 (5.3%)	0.0766	0 (0%)
Diarrhea	45 (16.0%)	22 (7.8%)	0.0039	0 (0%)
Bleeding	8 (2.8%)	7 (2.5%)	1.0000	0 (0%)

^a p values for categorical variables obtained by Fisher's exact test. Quantitative variables were analyzed by Mann–Whitney U-test. Abbreviations:;

IQR: Interquartile range.

Variable	Recovered patients (n=282)	Deceased patients (n=282)	P-value ^a	Misssingness (n: 564)
Comorbidities (%)				
Coronary heart disease	22 (7.8%)	25 (8.9%)	0.7609	0 (0%)
Heart failure	9 (3.2%)	21 (7.4%)	0.0374	0 (0%)
Hypertension	131 (46.5%)	162 (57.4%)	0.0114	0 (0%)
Thromboembolic disease	9 (3.2%)	10 (3.5%)	1.0000	0 (0%)
Dyslipidemia	17 (6.0%)	23 (8.2%)	0.4124	0 (0%)
Chronic obstructive pulmonary disease	43 (15.2%)	38 (13.5%)	0.6312	0 (0%)
Asthma	3 (1.1%)	2 (0.7%)	1.0000	0 (0%)
Chronic kidney disease	39 (13.8%)	51 (18.1%)	0.2058	0 (0%)
Chronic liver disease	2 (0.7%)	4 (1.4%)	0.6858	0 (0%)
Stroke	5 (1.8%)	13 (4.6%)	0.0910	0 (0%)
Gastroesophageal reflux disease	17 (6.0%)	6 (2.1%)	0.0311	0 (0%)
Hepatitis C	1 (0.4%)	0 (0.0%)	1.0000	0 (0%)
Hepatitis B	0 (0.0%)	0 (0.0%)	-	0 (0%)
HIV	1 (0.4%)	2 (0.7%)	1.0000	0 (0%)
TBC	2 (0.7%)	1 (0.4%)	1.0000	0 (0%)
Type II diabetes	63 (22.3%)	89 (31.6%)	0.0175	0 (0%)
Cancer	14 (5.0%)	23 (8.2%)	0.1729	0 (0%)
Obesity	16 (5.7%)	58 (20.6%)	< 1e-04	0 (0%)
Hypothyroidism	47 (16.7%)	51 (18.1%)	0.7390	0 (0%)
Autoimmune disease	10 (3.5%)	11 (3.9%)	1.0000	0 (0%)
Former smoking	32 (11.3%)	36 (12.8%)	0.6983	0 (0%)

Table 2. Comorbidities and hospital management of patients diagnosed with COVID-19.

Active smoking	3 (1.1%)	12 (4.3%)	0.0328	0 (0%)
In-hospital management on admission (%	(6)			
Corticosteroids	130 (46.1%)	163 (57.8%)	0.0069	0 (0%)
Azithromycin	2 (0.7%)	5 (1.8%)	0.4502	0 (0%)
Antibiotics	124 (44.0%)	186 (66.0%)	< 1e-04	0 (0%)
Ivermectin	0 (0.0%)	0 (0.0%)	-	0 (0%)
NSAIDs	112 (39.7%)	35 (12.4%)	< 1e-04	0 (0%)
ARBs	56 (19.9%)	26 (9.2%)	0.0005	0 (0%)
Bronchodilators	86 (30.5%)	88 (31.2%)	0.9274	0 (0%)
Anticoagulation	30 (10.6%)	33 (11.7%)	0.7894	0 (0%)
Antimalarials	1 (0.4%)	4 (1.4%)	0.3728	0 (0%)
Antiviral drugs	1 (0.4%)	0 (0.0%)	1.0000	0 (0%)
In-hospital management follow-up (%)				
Pronation therapy	26 (9.2%)	121 (42.9%)	< 1e-04	0 (0%)
Nasal cannula	154 (54.6%)	127 (45.0%)	0.0285	0 (0%)
Non-rebreather mask	42 (14.9%)	208 (73.8%)	< 1e-04	0 (0%)
High flow cannula	9 (3.2%)	38 (13.5%)	< 1e-04	0 (0%)
Orotracheal intubation	14 (5.0%)	169 (59.9%)	< 1e-04	0 (0%)
Dialysis	9 (3.2%)	51 (18.1%)	< 1e-04	0 (0%)
ICU admission	20 (7.1%)	126 (44.7%)	< 1e-04	0 (0%)
Inotropic or vasopressor support	14 (5.0%)	141 (50.0%)	< 1e-04	0 (0%)

^a p values for categorical variables obtained by Fisher's exact test. Quantitative variables were analyzed by Mann–Whitney U-test. Abbreviations: NSAIDs: Non-steroidal anti-inflammatory drugs; IQR: Interquartile range; ARBs: Angiotensin II receptor blockers; HIV: Human immunodeficiency virus; TBC: Tuberculosis; ICU: Intensive care unit; PaO₂/FiO₂: partial pressure of oxygen (PaO2) to inspired (FiO2) partial pressure of oxygen ratio.

Variable	Recovered patients (n=282)	Deceased patients (n=282)	P-value ^a	Misssingness (n: 564)			
Clinical outcomes (%)							
Renal alterations	37 (13.1%)	130 (46.1%)	< 1e-04	0 (0%)			
Co-infection	20 (7.1%)	57 (20.2%)	< 1e-04	0 (0%)			
Hematological alterations	146 (51.8%)	242 (85.8%)	< 1e-04	0 (0%)			
Thrombotic events	6 (2.1%)	18 (6.4%)	0.0199	0 (0%)			
Neurological alterations	22 (7.8%)	31 (11.0%)	0.2481	0 (0%)			
Cardiac alterations	18 (6.4%)	95 (33.7%)	< 1e-04	0 (0%)			
Paraclinics on admission (Median - IQR)			<u> </u>				
Hemoglobin (g/dL)	14.8 (13.5-16.2)	14.4 (12.4-15.8)	0.0086	106 (18.79%)			
Platelets (Cells/uL)	206,000 (170,000 -268,000)	217,000 (157,000 - 274,000)	0.8015	106 (18.79%)			
Leukocytes (Cells/uL)	7,860 (5,620 - 10,285)	10,670 (6,730 - 14,720)	< 1e-04	106 (18.79%)			
Lymphocytes (Cells/uL)	1,130 (740 - 1,650)	860 (585-1200)	< 1e-04	106 (18.79%)			
Neutrophils (Cells/uL)	5,700 (3,630 - 8,196)	8,915 (5,267 - 13,112)	< 1e-04	107 (18.97%)			
C-reactive protein (mg/L)	102.3 (40.2 - 171.2)	174.7 (85.8 - 267.5)	< 1e-04	247 (43.79%)			
Erythrocyte sedimentation rate (mm/hr)	22 (22 - 22)	18 (12 - 20)	0.3798	558 (98,94%)			
International normalized ratio	1.06 (1 - 1.17)	1.07 (0.99 - 1.2)	0.9196	453 (80.32%)			
Aspartate aminotransferase (U/L)	37 (27 - 59)	64.5 (41.8 - 97.5)	0.0002	474 (84.04%)			
Alanine aminotransferase (U/L)	30 (21.5 – 54.5)	46 (30 - 93.3)	0.0268	473 (83.87%)			
Albumin (gr/dL)	3.32 (2.97 - 3.48)	3.21 (2.43 - 3.43)	0.3918	543 (96.28%)			
Total bilirubin (mg/dL)	0.64 (0.45 - 0.87)	0.68 (0.49 - 1.09)	0.4640	422 (74.82%)			
Blood urea nitrogen (mg/dL)	18.4 (13.8 - 28.8)	26.3 (18.4 - 43.2)	< 1e-04	166 (29.43%)			

Table 3. Clinical outcomes and paraclinics on admission of patients diagnosed with COVID-19.

Creatinine (mg/dL)	0.99 (0.78 - 1.24)	1.16 (0.9 - 1.85)	< 1e-04	138 (24.47%)
Creatine kinase (U/L)	6.18 (6.18 - 6.18)	105 (78 - 135)	0.1432	558 (98.94%)
D-dimer (mg/dL)	0.775 (0.41 - 1.74)	1.52 (0.67 - 4.08)	< 1e-04	186 (32.98%)
Ferritin (ng/mL)	878.6 (495.1 - 1,501)	1,378 (731.2 - 2,475.5)	< 1e-04	211 (37.41%)
Lactic acid (mmol/L)	1.44 (1.14 - 1.99)	2.11 (1.5 – 3.37)	0.0180	443 (78.55%)
Lactate dehydrogenase (U/L)	298 (225.5 - 377.5)	466 (335.5 - 652)	< 1e-04	190 (33.69%)
Procalcitonin (ng/mL)	0.778 (0.55 - 1)	0.14 (0.09 – 0.19)	0.0641	558 (89.94%)
PaO ₂ /FiO ₂ (mmHg)	252.6 (211 - 297.80	115 (71.5 - 222.15)	< 1e-04	155 (27.48%)
Oxygen saturation (%)	92.9 (89.15 - 95.85)	90.2 (86 - 93,78)	0.0002	131 (23.23%)

^a p values for categorical variables obtained by Fisher's exact test. Quantitative variables were analyzed by Mann–Whitney U-test. Abbreviations: NSAIDs: Non-steroidal anti-inflammatory drugs; IQR: Interquartile range; ARBs: Angiotensin II receptor blockers; HIV: Human immunodeficiency virus; TBC: Tuberculosis; ICU: Intensive care unit; PaO₂/FiO₂: partial pressure of oxygen (PaO2) to inspired (FiO2) partial pressure of oxygen ratio.

Variable	Main Vs. Imputed Dataset 1	Main Vs. Imputed Dataset 2	Main Vs. Imputed Dataset 3	Main Vs. Imputed Dataset 4	Main Vs. Imputed Dataset 5
Paraclinics on admission					
Hemoglobin (g/dL)	0.4503	0.8956	0.7301	0.8204	0.7955
Platelets (Cells/uL)	0.9705	0.7900	0.4258	0.5854	0.8971
Leukocytes (Cells/uL)	0.9079	0.7048	0.5637	0.4226	0.8877
Lymphocytes (Cells/uL)	0.9808	0.7245	0.8874	0.9945	0.8053
Neutrophils (Cells/uL)	0.8364	0.4069	0.6002	0.2971	0.6169
C-reactive protein (mg/L)	0.7267	0.9855	0.6387	0.8920	0.4734
Total bilirubin (mg/dL)	0.1539	0.4270	0.7628	0.8548	0.7584
Blood urea nitrogen (mg/dL)	0.9875	0.5288	0.6392	0.3416	0.9320
Creatinine (mg/dL)	0.8553	0.7842	0.9174	0.6214	0.7608
D-dimer (mg/dL)	0.9702	0.9092	0.6611	0.9079	0.7723
Ferritin (ng/mL)	0.7442	0.5230	0.1959	0.8348	0.4637
Lactic acid (mmol/L)	0.2466	0.2657	0.3806	0.4587	0.2240
Lactate dehydrogenase (U/L)	0.7523	0.4675	0.9154	0.7937	0.5737
PaO2/FiO2 (mmHg)	0.9339	0.9456	0.6239	0.7643	0.5535
Oxygen saturation (%)	0.6625	0.9327	0.4655	0.6727	0.8556

^a p values for quantitative variables were analyzed by Mann–Whitney U-test. PaO2/FiO2: partial pressure of oxygen (PaO2) to inspired (FiO2) partial pressure of oxygen ratio.

Fig 1. Missing data and imputation. A. Histogram of frequency of missing variables in the total of patients included (n: 584). **B.** Heatmap for the distribution of missing data. **C.** Distribution of imputed variables by MICE. The red lines correspond to the five imputed datasets, whereas the blue line corresponds to the original dataset. MICE: Multiple imputations by chained equation.

Fig 2. Classification and regression trees (CART). This strategy estimated a predictive model and 14 clinical profiles, including respiratory distress, LDH, dyspnea, hemoglobin, D-dimer, ferritin, blood urea nitrogen, C-reactive protein, PaO₂/FiO₂, dysgeusia, total bilirubin, platelets, and gastroesophageal reflux disease. LDH: lactate dehydrogenase; PaO₂/FiO₂: partial pressure of oxygen (PaO₂) to inspired (FiO₂) partial pressure of oxygen ratio.



